What is Alector?
Founded in 2013 and headquartered in South San Francisco, Alector is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutics for neurodegenerative diseases. The company operates at the intersection of immunology and neuroscience, focusing on the development of therapies that harness the body's immune system to address the underlying causes of conditions like amyotrophic lateral sclerosis, Alzheimer's, and Parkinson's. By targeting the immune system's role in brain health, Alector aims to provide transformative solutions for elderly populations suffering from these debilitating disorders.
How much funding has Alector raised?
Alector has raised a total of $430.5M across 6 funding rounds:
Series C
$32M
Series D
$29.5M
Series E
$133M
Stock Offering
$176M
Debt
$50M
Debt
$10M
Series C (2015): $32M with participation from GV, Topspin Partners, Polaris Partners, Mission Bay Capital, OrbiMed, and MRL Ventures Fund
Series D (2016): $29.5M led by AbbVie, Dementia Discovery Fund, and Amgen Business Development
Series E (2018): $133M supported by Polaris Partners, Foresite Capital, GV, Amgen Business Development, AbbVie Ventures, Euclidean Capital, Section 32, Federated Kaufmann Fund, the Dementia Discovery Fund, MRL Ventures, Lilly Asia Ventures, Perceptive Advisors, Deerfield, New Leaf Venture Partners, Casdin Capital, OrbiMed, and Mission Bay Capital
Stock Issuance/Offering (2019): $176M, investors not publicly disclosed
Debt (2024): $50M backed by Hercules Capital
Debt (2024): $10M with participation from Hercules Capital
Key Investors in Alector
OrbiMed
OrbiMed is a specialized healthcare investment firm managing capital across biopharmaceuticals and medical devices, known for its deep expertise in life sciences and multi-stage investment strategies.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing strategic coaching and resources for growth.
GV
GV is a venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences, enterprise solutions, and frontier technology innovations.
What's next for Alector?
Looking ahead, Alector is poised to utilize its recent financing to bolster its clinical trial operations and expand its research capabilities. The strategic deployment of these funds will likely focus on advancing its lead therapeutic candidates through late-stage clinical trials, while simultaneously investing in the discovery of next-generation immune-modulating treatments. As the company matures, its ability to maintain strong partnerships with major biopharmaceutical entities and venture capital firms will be essential for scaling its operations and achieving long-term commercial viability in the competitive biotech sector.
See full Alector company page
